The daily use of low dose aspirin has been a mainstay of preventing strokes for decades. While there has always been a risk of bleeding associated with aspirin use, the benefits were thought to outweigh the risk.
Now new research led by Monash University has shown daily, low-dose aspirin doesn’t prevent strokes in relatively healthy people aged over 70. And it increases their risk of bleeding on the brain after falls or other injuries.
But if you’re taking aspirin, it doesn’t mean you should abruptly stop. It may still have a role to play in treating people at high risk of stroke. Or, after talking to your doctor, there might be better options available.
Read more: Hippocrates and willow bark? What you know about the history of aspirin is probably wrong
Why has aspirin been used to prevent strokes?
Aspirin is an anti-platelet medicine, which is commonly known as a blood-thinner. Platelets are the component of blood primarily responsible for its clotting action. They are what stop you from continuously bleeding any time you have a cut or scrape on your skin.
A stroke is when oxygen can’t get into the brain because of a burst or blocked blood vessel. A blockage can occur when platelets in the bloodstream form a clot and it gets stuck in the artery.
Because aspirin acts on platelets, it can help prevent the clots that can lead to a stroke.
But because aspirin acts on platelets, it can also increase the risk of unwanted bleeding, usually in the stomach. It can also increase your risk of bleeding more when you have another injury, like hitting your head.
Aspirin isn’t just used for the prevention of strokes. It is also the first aid treatment for someone undergoing a heart attack.
Findings of the Monash trial
New research from Australia and the United States reports results from the Aspirin in Reducing Events in the Elderly (ASPREE) trial.
The researchers examined the protective use of daily low-dose aspirin (100 mg) in nearly 2,000 people who were aged 70 years and older and had no history of heart disease or stroke and whose blood pressure and cholesterol were well managed.
When compared with placebo, aspirin didn’t reduce or increase the risk of stroke. Of the participants who took the aspirin, 195 or 4.6% had a stroke. Of those who took the placebo, 203 people or 4.7% had a stroke.
But it did statistically increase the rate of non-stroke bleeding in the participants’ brains, for example when they injured their head. Those on aspirin showed a rate of bleeding in the brain of 1.1% (108 participants) compared with 0.8% (79 people) for those on placebo. This is a relatively, low but serious, risk.
Read more: Daily low-dose aspirin doesn't reduce heart-attack risk in healthy people
These findings are not entirely new. Research published five years ago based on the same ASPREE trial showed a similar result: a higher rate of bleeding among those taking low-dose aspirin compared with placebo.
However as the study authors note, aspirin continues to be widely used for the prevention of stroke.
What are the study’s limitations?
The researchers examined aspirin in mostly people of white European heritage.
So we don’t know whether the results are translatable to people with different ethnic backgrounds. Genetics and ethnicity can significantly impact the efficacy and safety of some drugs.
The clinical trial only included people who were not significantly at risk of a stroke, and had no history of heart disease.
Younger age groups were not studied either, so we cannot make any conclusions about their use of low dose aspirin to prevent stroke.
It’s also possible the potential benefits and risks are different for those who have underlying heart problems or who have previously had a stroke and are therefore at higher risk of another stroke.
I’m taking aspirin, what should I do?
If you’re taking daily low-dose aspirin and are concerned by the results of the study, it’s important you don’t just stop taking your medicine. Speak to your doctor or pharmacist.
For people who are at high risk of having a stroke, or have previously had one, low-dose aspirin may remain their treatment of choice despite the slight bleeding risk.
If you’re at high risk of bleeding, for example because of falls and other accidents due to advanced age, frailty, or another underlying condition, your doctor may be able to reduce the amount of aspirin you take by adding in dipyridamole or prescribing a different medicine completely, such as clopidogrel.
Associate Professor Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance. He is a Fellow of the Royal Australian Chemical Institute, a member of the Australasian Pharmaceutical Science Association, and a member of the Australian Institute of Company Directors. Nial is the chief scientific officer of Vaihea Skincare LLC, a director of SetDose Pty Ltd a medical device company, and a Standards Australia panel member for sunscreen agents. Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design, and testing.
Associate Professor Tina Hinton has previously received funding from the Schizophrenia Research Institute (formerly Neuroscience Institute of Schizophrenia and Allied Disorders). She is currently a Board member of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists.
This article was originally published on The Conversation. Read the original article.
